Reported Saturday, Arrowhead's Plozasiran Delivers 83% Median Triglyceride Reduction In Severe hypertriglyceridemia Patients With Zero Acute Pancreatitis Events Over Two-Year Open-Label Extension Study

Arrowhead's drug Plozasiran demonstrated an 83% median reduction in triglycerides among patients with severe hypertriglyceridemia during a two-year Phase 2b Open-Label Expansion Study, with 96% of patients achieving triglyceride levels below 500 mg/dL. Notably, there were no reported acute pancreatitis events in patients receiving the treatment. The study also indicated favorable improvements in atherogenic lipoproteins and maintained a safety profile consistent with previous trials.